Immunexpress
Immunexpress is a molecular diagnostics company developing FDA-cleared PCR-based host-response gene expression tests (SeptiCyte RAPID) for rapid (~1 hour) sepsis diagnosis, running on the Biocartis Idylla platform and serving hospital ICUs and emergency departments globally.
- Company typePrivate
- Founded2006
- HeadquartersSeattle, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Immunexpress does
Immunexpress Inc. is a privately-held molecular diagnostics company headquartered in Seattle, USA, with R&D operations in Brisbane, Australia, focused on developing host-response-based clinical assays for the management of sepsis and immune disorders. The company's core product, SeptiCyte RAPID, is an FDA-cleared, CE-marked, and TGA-cleared PCR-based molecular diagnostic test that analyzes mRNA gene expression signatures from whole blood to differentiate non-infectious systemic inflammatory response syndrome (SIRS) from sepsis, producing a proprietary SeptiScore (0-15 across four probability bands) in approximately one hour. SeptiCyte RAPID runs exclusively on the Biocartis Idylla fully automated cartridge-based platform under a 2018 co-development and commercialization partnership, enabling low-hands-on-time deployment in hospital laboratories. The company also offers SeptiCyte LAB (a manual laboratory version) and has a pipeline product, SeptiCyte RAPID+, a second-generation nine-gene assay designed to additionally differentiate bacterial from viral sepsis in roughly 70 minutes.
The business model is anchored on cartridge/kit sales to hospital laboratories running on the Biocartis Idylla instrument, supplemented by platform equipment placement; pricing is quote-based and not publicly disclosed. Immunexpress pursues a sales-led, enterprise field sales go-to-market targeting hospital ICUs, emergency departments, and large healthcare systems, with adoption driven by peer-reviewed clinical validation studies, KOL endorsements, and multi-jurisdiction regulatory clearances (FDA, CE Mark, TGA pediatric). The company has raised approximately $67 million in disclosed equity funding from Debiopharm Group and Biocartis across 2012-2015 rounds, secured a $745K BARDA contract in 2019, and closed an undisclosed private round in October 2019. The customer base includes named collaborations with academic medical centers (Johns Hopkins, Emory, Brown, UCL, Amsterdam UMC) and US health systems (Intermountain, Providence, Cone Health, Northwell, Seattle Children's), with sepsis positioning addressing a market of 1.7 million annual US hospitalizations and over $41 billion in hospital costs.
Immunexpress firmographics
Firmographics- Name
- Immunexpress
- Legal name
- Immunexpress Inc.
- Website
- https://immunexpress.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Immunexpress is a molecular diagnostics company developing FDA-cleared PCR-based host-response gene expression tests (SeptiCyte RAPID) for rapid (~1 hour) sepsis diagnosis, running on the Biocartis Idylla platform and serving hospital ICUs and emergency departments globally.
- Ownership category
- akta.pro rank
Immunexpress industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- Medical Laboratories (621511)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA)
- akta.pro secondary industry
- Sepsis, Deterioration & Rapid Response CDS (HLACAGAF)
Keywords
Where Immunexpress is headquartered
LocationHeadquarters
- HQ city
- Seattle
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Immunexpress business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Others
Revenue model
- SeptiCyte RAPID Test Kits: Sale of diagnostic test cartridges and consumables for use on the Biocartis Idylla platform. Hospitals purchase cartridges for each test performed.
- Idylla Platform Equipment: Laboratory equipment sales or placement agreements with hospital laboratories for the Biocartis Idylla platform required to run SeptiCyte tests.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Test pricing for hospital laboratory use |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels6 records
Immunexpress product offering
Product offeringCore offering
Immunexpress develops and commercializes molecular diagnostic assays that analyze the host immune response from a whole blood sample to diagnose sepsis. Its flagship product, SeptiCyte RAPID, is a PCR-based cartridge test run on the Biocartis Idylla platform that delivers a SeptiScore (0–15) and differentiates sepsis from non-infectious SIRS in approximately one hour. Customers are hospital laboratories, ICUs, and emergency departments that need faster, more accurate sepsis triage than traditional 24–48 hour blood culture methods provide.
Product overview
Immunexpress offers a portfolio of molecular diagnostic products centered on SeptiCyte technology for sepsis detection. The core product, SeptiCyte RAPID, is a cartridge-based automated test running on the Biocartis Idylla platform that delivers results in approximately one hour by analyzing host immune response gene expression from whole blood. SeptiCyte LAB is the manual laboratory precursor that has been validated in extensive peer-reviewed clinical studies. The pipeline includes SeptiCyte RAPID+, a next-generation nine-gene expression assay designed to differentiate both sepsis from SIRS and bacterial from viral infections. All products leverage patented host immune response biomarkers and algorithms to provide objective sepsis probability scoring (SeptiScore).
Differentiator
Problem solved
Functional benefit
Brands
- SeptiCyte RAPID: FDA-cleared, CE-marked rapid molecular diagnostic test for sepsis that delivers results in approximately one hour using the Biocartis Idylla platform
- SeptiCyte LAB
- SeptiCyte RAPID+
Products and services
- SeptiCyte RAPID FDA-cleared, CE-marked, and TGA-cleared PCR-based molecular diagnostic cartridge that differentiates non-infectious systemic inflammatory response syndrome (SIRS) from sepsis in critically ill patients by analyzing host immune response gene expression signatures from whole blood. Delivers actionable results in approximately one hour on the Biocartis Idylla platform with a SeptiScore (0–15). For hospital laboratories, ICUs, and emergency departments.
- SeptiCyte LAB Manual laboratory version of the host-response sepsis diagnostic test, validated in multiple peer-reviewed studies and originally developed prior to the automated SeptiCyte RAPID cartridge. For clinical and research laboratory use in discriminating sepsis from SIRS.
Quantifiable outcome
- Results delivered in ~1 hour vs 24-48 hours for traditional blood cultures
- +5 more outcomes
Companies that use Immunexpress
Customer profileNamed customers12 records
Segments6 records
Ideal customer profiles2 records
Immunexpress technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability2 records
Feature5 records
Immunexpress partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered minor and core.
- NovacytminorExtended sepsis assay development partnership with Novacyt. Novacyt is a molecular diagnostics company specializing in infectious disease testing.
- BARDA (Biomedical Advanced Research and Development Authority)core$745K HHS contract awarded through BARDA for continued development of SeptiCyte for rapid and accurate diagnosis of sepsis. BARDA is part of HHS focused on advanced research and development of medical countermeasures.
- BiocartiscorePartnership announced January 2018 to develop and commercialize a fully automated SeptiCyte LAB/RAPID test for use on Biocartis' Idylla platform. Idylla is a fully automated, RT-PCR based molecular testing system with compact scalable design. The partnership enables SeptiCyte tests to run on Idylla in hospital laboratory settings.
- MARS ConsortiumminorCollaboration to improve care of sepsis patients through the MARS (Molecule, Antibody, RNA Signature) consortium focused on sepsis research and diagnostics.
- Sepsis AlliancecoreNon-profit organization dedicated to informing the public about sepsis dangers. Immunexpress partners with Sepsis Alliance on educational webinar programs focused on challenges of diagnosing sepsis. Collaboration supports awareness and clinical best-practices for early detection.
- UCL (University College London)minorAcademic collaborator presenting validation data on bacterial infection diagnosis and bacterial vs viral differentiation signatures.
- Amsterdam UMCminorAcademic collaborator on studies discriminating sepsis from SIRS using SeptiCyte technology.
- Brown UniversityminorAcademic collaborator on validation of host response assay for discriminating sepsis from SIRS in the ICU.
- Intermountain HealthminorHealthcare system collaborator on sepsis diagnosis agreement studies and cartridge-based vs manual sepsis diagnosis testing.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
Immunexpress competitors and assessment
Company assessmentBroad incumbents
- Qiagen: Qiagen is a broad molecular diagnostics and sample-prep incumbent with sepsis-related PCR assay content and a deep hospital lab channel. Its board overlap (former Digene/Qiagen executives sit on Immunexpress's board) reflects the strategic adjacency in molecular Dx.
- Cepheid (Danaher): Cepheid's GeneXpert is the most widely deployed rapid PCR platform in hospital labs, including for bloodstream infection/sepsis-related applications. It is the primary incumbent rapid molecular testing platform that Immunexpress must position against for ICU/ED workflows.
- bioMérieux: bioMérieux is the incumbent leader in clinical microbiology and sepsis-related diagnostics (blood culture, procalcitonin / BIOFIRE products) — the dominant workflow Immunexpress must displace in hospital labs, with extensive commercial reach and reimbursement infrastructure.
- Roche Diagnostics: Roche operates broad molecular diagnostics, immunoassays (procalcitonin / Elecsys BRAHMS PCT), and central lab platforms used in sepsis workups. As a large incumbent, it competes for hospital lab sepsis testing budgets across multiple assay formats.
- Abbott Diagnostics: Abbott offers molecular diagnostics platforms (e.g., m2000, Alinity m) and immunoassays used in sepsis evaluation, and is one of the larger IVD competitors for the hospital lab customer that Immunexpress targets.
Others
- Biocartis: Biocartis is the platform partner for SeptiCyte RAPID via the Idylla system. While not a direct commercial competitor, Biocartis's commercial priorities and Idylla installed-base trajectory directly determine Immunexpress's route to market and cartridge-volume opportunity.
Direct peers
- T2 Biosystems: T2 Biosystems markets T2Bacteria and T2Candida direct-from-blood molecular diagnostic panels for sepsis-causing pathogens, targeting the same ICU/critical care customer segment with rapid, cartridge-based testing — competing for hospital lab budgets and clinical workflow mindshare.
- Inflammatix: Inflammatix is developing host-response-based molecular diagnostics for acute infection and sepsis, targeting similar clinical use cases (rapid differentiation of infection vs inflammation) with a different biomarker signature — a direct competitor for clinical adoption and hospital lab accounts.
- Cytovale: Cytovale commercializes IntelliSep, an FDA-cleared rapid host-response sepsis diagnostic that runs on a different platform but competes directly with SeptiCyte RAPID for the same ICU/ED use case and customer (hospital labs). It is the most direct functional competitor in the rapid host-response sepsis Dx category.
Emerging players
- Prenosis: Prenosis developed Sepsis ImmunoScore, an FDA-cleared AI-driven host-response diagnostic for sepsis risk, overlapping with Immunexpress on the host-response approach and sepsis decision support category, though using immunoassay rather than PCR.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Immunexpress social profiles
Digital presenceImmunexpress compliance and trust
Trust signalCompliance4 records
Immunexpress financial estimates
Financial estimateRevenue estimate
Valuation estimate
Immunexpress leadership team
Management profileNumber of profiles
Profiles16 records
Immunexpress funding detail
Funding detailFunding overview
Funding rounds6 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Immunexpress M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Immunexpress
What does Immunexpress do?
Immunexpress develops and commercializes molecular diagnostic assays that analyze the host immune response from a whole blood sample to diagnose sepsis. Its flagship product, SeptiCyte RAPID, is a PCR-based cartridge test run on the Biocartis Idylla platform that delivers a SeptiScore (0–15) and differentiates sepsis from non-infectious SIRS in approximately one hour. Customers are hospital laboratories, ICUs, and emergency departments that need faster, more accurate sepsis triage than traditional 24–48 hour blood culture methods provide.
Is Immunexpress a public or private company?
Immunexpress is a private company. It is classified as venture growth investor backed and is currently operating.
When was Immunexpress founded?
Immunexpress was founded in 2006. It employs 11 to 50 people.
Where is Immunexpress based?
Immunexpress is headquartered in Seattle, United States, in the North America region.
How does Immunexpress make money?
Two revenue lines are on record. SeptiCyte RAPID Test Kits are the primary driver. The others are idylla Platform Equipment.
Who are Immunexpress's main competitors?
Broad incumbents on record are Qiagen, Cepheid (Danaher), bioMérieux, Roche Diagnostics and Abbott Diagnostics. Biocartis is listed as an others. Direct peers are T2 Biosystems, Inflammatix and Cytovale. Prenosis is listed as an emerging player.
Does Immunexpress have an API?
No public API is recorded for Immunexpress.
What industry is Immunexpress in?
Immunexpress's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays), with a secondary code of HLACAGAF, Sepsis, Deterioration & Rapid Response CDS. Its NAICS code is 621511 and its SIC code is 2835.